BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 8494726)

  • 1. Mechanisms of selective killing of neuroblastoma cells by natural killer cells and lymphokine activated killer cells. Potential for residual disease eradication.
    Foreman NK; Rill DR; Coustan-Smith E; Douglass EC; Brenner MK
    Br J Cancer; 1993 May; 67(5):933-8. PubMed ID: 8494726
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dendritic cells for NK/LAK activation: rationale for multicellular immunotherapy in neuroblastoma patients.
    Valteau-Couanet D; Leboulaire C; Maincent K; Tournier M; Hartmann O; Bénard J; Beaujean F; Boccaccio C; Zitvogel L; Angevin E
    Blood; 2002 Oct; 100(7):2554-61. PubMed ID: 12239169
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro induction of lymphokine-activated killer (LAK) activity in patients with neuroblastoma.
    Handgretinger R; Bruchelt G; Kimmig A; Dopfer R; Niethammer D; Treuner J
    Pediatr Hematol Oncol; 1989; 6(4):307-17. PubMed ID: 2641703
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differentiation-related expression of adhesion molecules and receptors on human neuroblastoma tissues, cell lines and variants.
    Gross N; Favre S; Beck D; Meyer M
    Int J Cancer; 1992 Aug; 52(1):85-91. PubMed ID: 1354203
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD18/CD54(+CD102), CD2/CD58 pathway-independent killing of lymphokine-activated killer (LAK) cells against glioblastoma cell lines T98G and U373MG.
    Komatsu F; Kajiwara M
    Oncol Res; 2000; 12(1):17-24. PubMed ID: 11061342
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased susceptibility of IFN-gamma-treated neuroblastoma cells to lysis by lymphokine-activated killer cells: participation of ICAM-1 induction on target cells.
    Naganuma H; Kiessling R; Patarroyo M; Hansson M; Handgretinger R; Grönberg A
    Int J Cancer; 1991 Feb; 47(4):527-32. PubMed ID: 1671670
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lysis of neuroblastoma cell lines by human natural killer cells activated by interleukin-2 and interleukin-12.
    Rossi AR; Pericle F; Rashleigh S; Janiec J; Djeu JY
    Blood; 1994 Mar; 83(5):1323-8. PubMed ID: 7906963
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transfection of the mouse ICAM-1 gene into murine neuroblastoma enhances susceptibility to lysis, reduces in vivo tumorigenicity and decreases ICAM-2-dependent killing.
    Katsanis E; Bausero MA; Xu H; Orchard PJ; Xu Z; McIvor RS; Brian AA; Blazar BR
    Cancer Immunol Immunother; 1994 Feb; 38(2):135-41. PubMed ID: 7905790
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phorbol 12-myristate 13-acetate induces resistance of human melanoma cells to natural-killer- and lymphokine-activated-killer-mediated cytotoxicity.
    Correale P; Procopio A; Celio L; Caraglia M; Genua G; Coppola V; Pepe S; Normanno N; Vecchio I; Palmieri G
    Cancer Immunol Immunother; 1992; 34(4):272-8. PubMed ID: 1371427
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of human interleukin 3 on the susceptibility of fresh leukemia cells to interleukin-2-induced lymphokine activated killing activity.
    Cesano A; Lista P; Bellone G; Geuna M; Brizzi MF; Rossi PR; Pegoraro L; Oberholtzer E; Matera L
    Leukemia; 1992 Jun; 6(6):567-73. PubMed ID: 1376379
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Progression of natural immunity during one-year treatment of residual disease in neuroblastoma patients with high doses of interleukin-2 after autologous bone marrow transplantation.
    Martí F; Pardo N; Peiró M; Bertran E; Amill B; García J; Cubells J; Rueda F
    Exp Hematol; 1995 Dec; 23(14):1445-52. PubMed ID: 8542930
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relation of natural killer cell line NK-92-mediated cytolysis (NK-92-lysis) with the surface markers of major histocompatibility complex class I antigens, adhesion molecules, and Fas of target cells.
    Komatsu F; Kajiwara M
    Oncol Res; 1998; 10(10):483-9. PubMed ID: 10338151
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The relationship between multi-drug resistance and resistance to natural-killer-cell and lymphokine-activated killer-cell lysis in human leukemic cell lines.
    Treichel RS; Olken S
    Int J Cancer; 1992 Jan; 50(2):305-10. PubMed ID: 1370437
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GM-CSF enhances IL-2-activated natural killer cell lysis of clonogenic AML cells by upregulating target cell expression of ICAM-1.
    Bendall LJ; Kortlepel K; Gottlieb DJ
    Leukemia; 1995 Apr; 9(4):677-84. PubMed ID: 7723403
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction of intercellular adhesion molecule 1 on small cell lung carcinoma cell lines by gamma-interferon enhances spontaneous and bispecific anti-CD3 x antitumor antibody-directed lymphokine activated killer cell cytotoxicity.
    Azuma A; Yagita H; Matsuda H; Okumura K; Niitani H
    Cancer Res; 1992 Sep; 52(18):4890-4. PubMed ID: 1381273
    [TBL] [Abstract][Full Text] [Related]  

  • 16. VLA-6 (CDw49f) is an important adhesion molecule in NK cell-mediated cytotoxicity following autologous or allogeneic bone marrow transplantation.
    Lowdell MW; Shamim F; Hamon M; Macdonald ID; Prentice HG
    Exp Hematol; 1995 Dec; 23(14):1530-4. PubMed ID: 8542943
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lymphokine-activated killer function following autologous bone marrow transplantation for refractory hematological malignancies.
    Higuchi CM; Thompson JA; Cox T; Lindgren CG; Buckner CD; Fefer A
    Cancer Res; 1989 Oct; 49(20):5509-13. PubMed ID: 2477142
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The development of cell mediated immunity: very young children have strong LAK activity.
    Pierson GR; Evans AE; Zier KS
    J Clin Lab Immunol; 1990 Feb; 31(2):51-4. PubMed ID: 1966985
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The nonclassical major histocompatibility complex molecule Qa-2 protects tumor cells from NK cell- and lymphokine-activated killer cell-mediated cytolysis.
    Chiang EY; Henson M; Stroynowski I
    J Immunol; 2002 Mar; 168(5):2200-11. PubMed ID: 11859106
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-dose systemic interleukin-2 therapy in stage IV neuroblastoma for one year after autologous bone marrow transplantation: pilot study.
    Pardo N; Martí F; Fraga G; Illa J; Badell I; Peiró M; Bertran E; García J; Rueda F; Cubells J
    Med Pediatr Oncol; 1996 Dec; 27(6):534-9. PubMed ID: 8888813
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.